Lipigon currently manages three drug projects, with Lipisense^® being the most advanced.

• Lipisense^®
  An RNA drug targeting elevated triglycerides.

• Dyslipidemia
  A small molecule project for dyslipidemia (general lipid disorders). Project in partnership with HitGen, Inc.

• CAP
  An RNA drug project for Community-Acquired Pneumonia (CAP).

See the full pipeline